Celcuity (CELC) just made a couple of moves that could significantly widen the addressable market for its lead cancer drug, gedatolisib. On Thursday, the company announced it's amending its Phase 3 VIKTORIA-2 trial to include patients with endocrine-sensitive HR+/HER2- advanced breast cancer in the first-line setting. That's on top of the endocrine-resistant population the trial was already studying.
The company also said it's making progress on a subcutaneous (injectable) formulation of gedatolisib, which would be a lot more convenient for patients than the current intravenous infusion. Needham analyst Gil Blum, who reiterated a Buy rating and $157 price target on the stock, called these moves "logical steps toward expanding geda's long-term commercial opportunity."
Why Endocrine-Sensitive Patients Matter
Originally, VIKTORIA-2 was focused on patients whose cancer had become resistant to endocrine therapy. That's a meaningful group, but the endocrine-sensitive population — patients who haven't yet developed resistance — is much larger. By including both groups, Celcuity is essentially trying to position gedatolisib as a frontline treatment for a broader swath of breast cancer patients.
The company said it met with the FDA through a Type B meeting before finalizing the amended trial design. That suggests the agency is on board with the expanded approach.
Celcuity's chief medical officer, Igor Gorbatchevsky, pointed to some impressive data from an earlier Phase 1b trial that tested gedatolisib in combination with palbociclib and letrozole in endocrine-sensitive patients. That study produced a median progression-free survival of 48.6 months, a median overall survival of 77.3 months, and an objective response rate of 79%. Those are the kinds of numbers that get analysts excited.
Earlier this month, Celcuity also reported that its Phase 3 VIKTORIA-1 trial showed a statistically significant improvement in progression-free survival for gedatolisib compared to standard therapies. So the drug is building a solid case for itself.
An Injectable Version Could Be a Game Changer
Separately, Celcuity said it filed its first patent application with the USPTO for a subcutaneous version of gedatolisib. Instead of sitting in a clinic for an infusion, patients could get a quick injection. That's a big deal for a drug that might be used over long periods — especially if it moves into the frontline setting, where patients could be on treatment for years.
Needham noted that the development of a subcutaneous formulation is "a meaningful advancement ahead of potential expansion into the much larger frontline population." The company is still working to establish clinical equivalence with the intravenous version, but the direction is clear.
Financially, Celcuity looks well-positioned to execute on these plans. The company ended the first quarter of 2026 with $387.1 million in cash, cash equivalents, and short-term investments, which it says should fund operations through 2027.
As of Friday's close, Celcuity shares were down 1.73% at $132.39. But with a potential expansion into a much larger patient population and a more convenient drug formulation in the works, the long-term story is getting more interesting.
